Latest news with #VikingTherapeutics
Yahoo
12 hours ago
- Business
- Yahoo
Why This Weight Loss Drug Company's Stock Surged Today
Investors are optimistic about the initiation of a phase 3 trial for a weight loss drug from Viking Therapeutics. The real value in the biopharmaceutical company may lie in the oral formulation of the drug. 10 stocks we like better than Viking Therapeutics › Shares in biopharmaceutical company Viking Therapeutics (NASDAQ: VKTX) were up by 6.3% at 12:30 a.m. ET today. The move likely stems from the market digesting the previous day's news that Viking had initiated a phase 3 trial of its most promising program in its pipeline, namely VK2375, a treatment for metabolic disorders, including obesity. There are probably two key reasons why the market likes the initiation of a phase 3 trial: VK2375 is a dual GLP-1/GIP receptor agonist similar to Eli Lilly's blockbuster weight loss drug Zepbound. Viking is developing VK2375 in both subcutaneous (under the skin) and oral formulations. The subcutaneous phase 3 trial is currently underway, while the phase 2 oral dosing trial results are expected to be released later this year. For reference, Novo Nordisk also offers a highly successful weight loss drug, Wegovy, a GLP-1 receptor agonist. While Viking Therapeutics, with a $3.2 billion market capitalization, will face challenges in competing with Eli Lilly's Zepbound unless it can demonstrate superior efficacy in the phase 3 trial, the real value in the business may lie in the oral formulation. There are obvious convenience and accessibility advantages to an oral formulation over a subcutaneous one, and a successful phase 2 trial may encourage a much larger pharmaceutical company to consider acquiring the company to take it through phase 3. As such, look out for the phase 2 results later in the year. In addition, note that Novo Nordisk has submitted to the FDA for approval of an oral formulation of Wegovy , and Eli Lilly recently reported positive results in a phase 3 trial for an oral GLP-1 agonist, orforglipron. All this means that the field is getting crowded. Before you buy stock in Viking Therapeutics, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the for investors to buy now… and Viking Therapeutics wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $687,731!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $945,846!* Now, it's worth noting Stock Advisor's total average return is 818% — a market-crushing outperformance compared to 175% for the S&P 500. Don't miss out on the latest top 10 list, available when you join . See the 10 stocks » *Stock Advisor returns as of June 23, 2025 Lee Samaha has no position in any of the stocks mentioned. The Motley Fool recommends Novo Nordisk and Viking Therapeutics. The Motley Fool has a disclosure policy. Why This Weight Loss Drug Company's Stock Surged Today was originally published by The Motley Fool Erreur lors de la récupération des données Connectez-vous pour accéder à votre portefeuille Erreur lors de la récupération des données Erreur lors de la récupération des données Erreur lors de la récupération des données Erreur lors de la récupération des données
Yahoo
19 hours ago
- Business
- Yahoo
3 Growth Stocks I'm Loading Up On
Viking Therapeutics advances its dual GLP-1/GIP obesity drug into Phase 3 trials, entering a $100 billion weight loss market. Applied Digital's $7 billion CoreWeave partnership transforms it into an AI infrastructure powerhouse amid soaring data center demand. Palantir defies gravity with a 90% gain in 2025 as government AI contracts multiply. 10 stocks we like better than Viking Therapeutics › Growth stocks are having a moment. Several small- and mid-cap stocks have suddenly jumped 40% or more in the past 30 days. The catalyst? Investors are piling into innovative growth companies in response to the rapid pace of development of artificial intelligence (AI), alongside the potential positive impact of the Trump administration's efforts to roll back regulations. Here are three incredible growth stocks I'm loading up on right now. Viking Therapeutics (NASDAQ: VKTX) just initiated its VANQUISH Phase 3 clinical program for VK2735, its dual GLP-1/GIP receptor agonist targeting obesity. This move could transform the $3 billion biotech into a pharmaceutical powerhouse. The Phase 2 VENTURE study results were compelling. Patients achieved up to 14.7% body-weight reduction after just 13 weekly doses. Even better, 95% of gastrointestinal side effects were mild or moderate -- addressing the key weakness of current obesity treatments. Viking is entering a market Morgan Stanley projects will reach $150 billion by 2035. While Eli Lilly's Zepbound and Novo Nordisk's Wegovy require weekly injections, Viking's developing an oral formulation that could dramatically expand the addressable market. The company's also planning a monthly maintenance regimen study later this year. With 4,500 patients targeted for the obesity trial and 1,100 for diabetes, Viking's comprehensive approach could support premium pricing. At its current valuation, Viking trades at a fraction of recent pharma acquisitions. If VK2735 hits its endpoints, this stock could easily double or triple. Applied Digital Corporation (NASDAQ: APLD) just landed a $7 billion, 15-year hosting agreement with CoreWeave -- validation of its high-performance computing strategy. CoreWeave, backed by Nvidia, chose Applied Digital for 250 megawatts at its Ellendale campus in North Dakota, with an option for another 150 megawatts. Recent Q3 FY2025 results missed revenue expectations ($52.9 million vs. $62.9 million expected), but the company maintains strong partnerships. Management projects significant growth as the Ellendale facility comes online in phases starting Q4 2025. Despite the near-term revenue miss, the long-term opportunity remains massive. The AI boom is driving unprecedented demand for high-performance computing infrastructure, and Applied Digital's partnership with CoreWeave positions it perfectly to capture this growth. Palantir Technologies (NASDAQ: PLTR) stock looks insanely overvalued at 263 times forward earnings. But sometimes, the market knows something that valuation models don't. The stock's up 90% this year -- the best performer among companies valued over $5 billion -- because its technology is becoming indispensable. The Pentagon just boosted Palantir's Maven Smart System budget to $1.3 billion over four years -- a $795 million increase. The company is negotiating with the Social Security Administration and the IRS for new contracts. CEO Alex Karp's recent Fannie Mae partnership for mortgage-fraud detection shows expansion into new verticals. Commercial revenue is accelerating, too, growing 33% year over year to $397 million. Total revenue was $884 million, a 39% increase, beating expectations. The combination of expanding government contracts and accelerating commercial adoption suggests Palantir's software is becoming the standard for AI deployment across both sectors. Wall Street loves predictable businesses with proven models. That's why it often misses the biggest winners. Viking's oral alternative -- if proven safe and effective -- could capture millions of patients who won't use injectables. Applied Digital is building tomorrow's AI infrastructure while others debate valuations. Palantir's turning the federal government into a recurring revenue stream. Each offers a fundamentally better solution to a massive problem -- and the market's too focused on near-term metrics to notice. Before you buy stock in Viking Therapeutics, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the for investors to buy now… and Viking Therapeutics wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $689,813!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $906,556!* Now, it's worth noting Stock Advisor's total average return is 809% — a market-crushing outperformance compared to 175% for the S&P 500. Don't miss out on the latest top 10 list, available when you join . See the 10 stocks » *Stock Advisor returns as of June 23, 2025 George Budwell has positions in Nvidia, Palantir Technologies, and Viking Therapeutics and has the following options: long January 2026 $55 calls on Viking Therapeutics, long January 2026 $60 calls on Viking Therapeutics, and long January 2027 $60 calls on Viking Therapeutics. The Motley Fool has positions in and recommends Nvidia and Palantir Technologies. The Motley Fool recommends Novo Nordisk and Viking Therapeutics. The Motley Fool has a disclosure policy. 3 Growth Stocks I'm Loading Up On was originally published by The Motley Fool
Globe and Mail
2 days ago
- Business
- Globe and Mail
3 Growth Stocks I'm Loading Up On
Growth stocks are having a moment. Several small- and mid-cap stocks have suddenly jumped 40% or more in the past 30 days. The catalyst? Investors are piling into innovative growth companies in response to the rapid pace of development of artificial intelligence (AI), alongside the potential positive impact of the Trump administration's efforts to roll back regulations. Here are three incredible growth stocks I'm loading up on right now. A weight loss wildcard Viking Therapeutics (NASDAQ: VKTX) just initiated its VANQUISH Phase 3 clinical program for VK2735, its dual GLP-1/GIP receptor agonist targeting obesity. This move could transform the $3 billion biotech into a pharmaceutical powerhouse. The Phase 2 VENTURE study results were compelling. Patients achieved up to 14.7% body-weight reduction after just 13 weekly doses. Even better, 95% of gastrointestinal side effects were mild or moderate -- addressing the key weakness of current obesity treatments. Viking is entering a market Morgan Stanley projects will reach $150 billion by 2035. While Eli Lilly's Zepbound and Novo Nordisk's Wegovy require weekly injections, Viking's developing an oral formulation that could dramatically expand the addressable market. The company's also planning a monthly maintenance regimen study later this year. With 4,500 patients targeted for the obesity trial and 1,100 for diabetes, Viking's comprehensive approach could support premium pricing. At its current valuation, Viking trades at a fraction of recent pharma acquisitions. If VK2735 hits its endpoints, this stock could easily double or triple. An AI infrastructure play Applied Digital Corporation (NASDAQ: APLD) just landed a $7 billion, 15-year hosting agreement with CoreWeave -- validation of its high-performance computing strategy. CoreWeave, backed by Nvidia, chose Applied Digital for 250 megawatts at its Ellendale campus in North Dakota, with an option for another 150 megawatts. Recent Q3 FY2025 results missed revenue expectations ($52.9 million vs. $62.9 million expected), but the company maintains strong partnerships. Management projects significant growth as the Ellendale facility comes online in phases starting Q4 2025. Despite the near-term revenue miss, the long-term opportunity remains massive. The AI boom is driving unprecedented demand for high-performance computing infrastructure, and Applied Digital's partnership with CoreWeave positions it perfectly to capture this growth. A government goldmine Palantir Technologies (NASDAQ: PLTR) stock looks insanely overvalued at 263 times forward earnings. But sometimes, the market knows something that valuation models don't. The stock's up 90% this year -- the best performer among companies valued over $5 billion -- because its technology is becoming indispensable. The Pentagon just boosted Palantir's Maven Smart System budget to $1.3 billion over four years -- a $795 million increase. The company is negotiating with the Social Security Administration and the IRS for new contracts. CEO Alex Karp's recent Fannie Mae partnership for mortgage-fraud detection shows expansion into new verticals. Commercial revenue is accelerating, too, growing 33% year over year to $397 million. Total revenue was $884 million, a 39% increase, beating expectations. The combination of expanding government contracts and accelerating commercial adoption suggests Palantir's software is becoming the standard for AI deployment across both sectors. Three disruptions, one strategy Wall Street loves predictable businesses with proven models. That's why it often misses the biggest winners. Viking's oral alternative -- if proven safe and effective -- could capture millions of patients who won't use injectables. Applied Digital is building tomorrow's AI infrastructure while others debate valuations. Palantir's turning the federal government into a recurring revenue stream. Each offers a fundamentally better solution to a massive problem -- and the market's too focused on near-term metrics to notice. Should you invest $1,000 in Viking Therapeutics right now? Before you buy stock in Viking Therapeutics, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Viking Therapeutics wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $689,813!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $906,556!* Now, it's worth noting Stock Advisor 's total average return is809% — a market-crushing outperformance compared to175%for the S&P 500. Don't miss out on the latest top 10 list, available when you join Stock Advisor. See the 10 stocks » *Stock Advisor returns as of June 23, 2025 George Budwell has positions in Nvidia, Palantir Technologies, and Viking Therapeutics and has the following options: long January 2026 $55 calls on Viking Therapeutics, long January 2026 $60 calls on Viking Therapeutics, and long January 2027 $60 calls on Viking Therapeutics. The Motley Fool has positions in and recommends Nvidia and Palantir Technologies. The Motley Fool recommends Novo Nordisk and Viking Therapeutics. The Motley Fool has a disclosure policy.
Yahoo
3 days ago
- Health
- Yahoo
Viking Therapeutics Begins Phase 3 Trial of Dual Agonist VK2735 in Obesity
Viking Therapeutics (VKTX) said Wednesday it has started a phase 3 trial of VK2735, its dual agonist Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
7 days ago
- Business
- Yahoo
2 Biotech Stocks to Buy Before They Soar 84% and 240%, According to Certain Wall Street Analysts
These biotech companies have several catalysts ahead -- and in the past have soared on good news. They both offer innovative candidates that could result in game-changing treatments for patients. 10 stocks we like better than Viking Therapeutics › If you're looking to add growth to your portfolio, biotech stocks can be a great choice. Exciting research is happening in these companies' labs, and in some cases, game-changing treatment candidates are approaching important milestones or even going over the finish line. As an investor in these companies, you can benefit as they report positive clinical trial news, score a regulatory approval, or start generating product revenue. Wall Street considers two candidates extremely compelling right now, with forecasts for potential gains of more than 80% and 200% in the coming 12 months. One of these players is working in the high-growth area of weight loss drugs, and the other candidate showed its strengths by winning the world's first-ever approval of a product based on CRISPR gene editing. Let's check out these two biotech stocks to buy before they skyrocket. Viking Therapeutics (NASDAQ: VKTX) soared early last year when it reported strong data from the phase 2 trial of its weight loss candidate, VK2735, but the stock has since given back those gains and is trading closer to the level it was at prior to that data announcement. Since, the company has continued to advance VK2735 in injectable form and a version in pill form, and demand for these sorts of drugs remains high -- these are two reasons to believe that Viking has the potential to take off again. And catalysts may be on the horizon. The drug works in a manner similar to Eli Lilly's blockbuster tirzepatide, sold under the names Mounjaro and Zepbound. These drugs interact with hormones involved in digestion and have helped people quickly and safely lose weight. Viking is beginning the phase 3 trial for injectable VK2735 in the second quarter and expects data from its phase 2 trial of the pill version in the second half. Any data announcements could result in big moves for the stock, as there is plenty of room for a new company to enter the weight loss drug market -- one forecast to approach $100 billion in a few years. Wall Street is optimistic about Viking's prospects, with the average price forecast predicting an increase of about 240% in the stock price from today's level. Of course, Viking depends heavily on the outcome of these trials, so some risk is involved -- but data have been strong, so growth investors may want to get in on Viking now to potentially post a big win later. CRISPR Therapeutics (NASDAQ: CRSP) stock surged in the year leading up to a major milestone: its first product approval. But since last year's launch of Casgevy, a gene-editing treatment for blood disorders, the stock has been on the decline. Sometimes, investors buy a stock well before the company wins approval or launches a product, then lock in gains after the good news lands -- and I think this is what's happened here. But what this does is offer us a chance to get in at a very good price on a promising company that could deliver fantastic news down the road. Casgevy, as a gene-editing treatment, requires a longer time to roll out than a pill or injection, as it includes several steps that happen over a period of months. The company recently said new patient initiations should increase "significantly" this year -- so there's reason to be optimistic about revenue growth ahead. CRISPR Therapeutics also recently reported positive phase 1 data for a gene editing candidate addressing the problem of high cholesterol. And the company expects to report data soon from a phase 1 trial of a candidate targeting patients with elevated levels of lipoprotein(a) -- a risk factor for cardiovascular events. These could represent huge markets for CRISPR Therapeutics if the candidates reach the finish line, and in the meantime, any potential positive news could boost the stock. The company also expects other trial updates in candidates for oncology and autoimmune diseases this year -- so this biotech's calendar is full of possible catalysts. Wall Street's average price forecast calls for an 84% gain for CRISPR Therapeutics from today's price -- if all goes well in clinical trials and Casgevy starts to show revenue growth, now could represent a golden buying opportunity for growth investors. Before you buy stock in Viking Therapeutics, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the for investors to buy now… and Viking Therapeutics wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $664,089!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $881,731!* Now, it's worth noting Stock Advisor's total average return is 994% — a market-crushing outperformance compared to 172% for the S&P 500. Don't miss out on the latest top 10 list, available when you join . See the 10 stocks » *Stock Advisor returns as of June 9, 2025 Adria Cimino has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends CRISPR Therapeutics. The Motley Fool recommends Viking Therapeutics. The Motley Fool has a disclosure policy. 2 Biotech Stocks to Buy Before They Soar 84% and 240%, According to Certain Wall Street Analysts was originally published by The Motley Fool
